Metabolic & Endocrine
NASH/MASH
11
Pipeline Programs↗
6
Active Trials↗
9
Companies Involved↗
NASH/MASH is an emerging landscape with 11 programs across 9 companies. The most active players are Eli Lilly, Boehringer Ingelheim, Altimmune. 4 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Analysis
Modality Breakdown
11programs
Peptide545%
Small molecule436%
Protein / enzyme218%
Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
7
clinical trials
Recruiting3 · 43%
Active, not recruiting3 · 43%
Completed1 · 14%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)